- Poster presentation
- Open Access
Comparison of contrast enhanced magnetic resonance angiography (CE-MRA) and non contrast enhanced MRA for imaging of the carotid arteries
© Kramer et al; licensee BioMed Central Ltd. 2010
Published: 21 January 2010
Since the introduction of contrast enhanced MRA this technique is regarded as the standard of reference for imaging of almost all vascular territories with MRI. However, a few years ago a direct link between the application of Gadolinium (Gd) containing contrast agents and the development of a disease call nephrogenic systemic firbosis (NSF) was discovered. Due to this fact the need for a non contrast enhanced technique for imaging arterial and venous vessels with MRI experiences a renaissance.
To evaluate image quality and diagnostic accuracy of a non contrast enhanced magnetic resonance angiography (MRA) technique for imaging of the carotid arteries compared to standard contrast enhanced (CE) MRA.
32 consecutive patients (62 ± 16 y, 13 m/19 f) with s/o acute brain ischemia referred for carotid MRA were enrolled in the study. All MR exams were performed on a 3.0 T system (Magnetom Verio, Siemens Healthcare) and patients underwent both, CE-MRA (3D T1 Flash, 12 ml standard 0.5 molar contrast agent) and non-CE-MRA (ECG gated TrueFISP). Both techniques featured a spatial resolution of 0.9 × 0.9 × 0.9 mm3, acquisition time was 0:18 min for CE-MRA and heart rate dependent approximately 5:00 min for non-CE-MRA. Image quality was rated in terms of delineation of the vessel lumen, signal intensity within the vessel and diagnostic confidence by two readers on a 4 point scale whereas 4 stands for best score. Accuracy of quantitative measurements was evaluated by assessing the cross-sectional vessel area at three predefined levels identical for both techniques in the area of the carotid bifurcation.
Non-CE-MRA can serve as an alternative for CE-MRA without a significantly different image quality or diagnostic accuracy. This is especially interesting in patients with an impaired renal function to reduce the risk of NSF. However, the significantly longer acquisition time is still a drawback.
This article is published under license to BioMed Central Ltd.